Aerovate Therapeutics Statistics
Share Statistics
Aerovate Therapeutics has 28.87M shares outstanding. The number of shares has increased by 3.63% in one year.
| Shares Outstanding | 28.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.59M |
| Failed to Deliver (FTD) Shares | 2.00K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 1.86M, so 6.43% of the outstanding shares have been sold short.
| Short Interest | 1.86M |
| Short % of Shares Out | 6.43% |
| Short % of Float | 9.48% |
| Short Ratio (days to cover) | 8.06 |
Valuation Ratios
The PE ratio is -7.89 and the forward PE ratio is -2.66.
| PE Ratio | -7.89 |
| Forward PE | -2.66 |
| PS Ratio | 0 |
| Forward PS | 1.9 |
| PB Ratio | 5.44 |
| P/FCF Ratio | -10.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aerovate Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.04, with a Debt / Equity ratio of 0.
| Current Ratio | 7.04 |
| Quick Ratio | 7.04 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.69% and return on capital (ROIC) is -73.98%.
| Return on Equity (ROE) | -0.69% |
| Return on Assets (ROA) | -0.59% |
| Return on Capital (ROIC) | -73.98% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.48M |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 56.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.38% in the last 52 weeks. The beta is 1, so Aerovate Therapeutics 's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -86.38% |
| 50-Day Moving Average | 2.57 |
| 200-Day Moving Average | 8.32 |
| Relative Strength Index (RSI) | 59.77 |
| Average Volume (20 Days) | 785.79K |
Income Statement
| Revenue | n/a |
| Gross Profit | -96.00K |
| Operating Income | -81.41M |
| Net Income | -75.52M |
| EBITDA | -81.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.87 |
Balance Sheet
The company has 23.49M in cash and 675.00K in debt, giving a net cash position of 22.82M.
| Cash & Cash Equivalents | 23.49M |
| Total Debt | 675.00K |
| Net Cash | 22.82M |
| Retained Earnings | -163.42M |
| Total Assets | 90.96M |
| Working Capital | 80.29M |
Cash Flow
In the last 12 months, operating cash flow was -56.78M and capital expenditures -142.00K, giving a free cash flow of -56.92M.
| Operating Cash Flow | -56.78M |
| Capital Expenditures | -142.00K |
| Free Cash Flow | -56.92M |
| FCF Per Share | -2.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVTE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -107.49% |
| FCF Yield | -73.69% |
Analyst Forecast
The average price target for AVTE is $2, which is -25.1% lower than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | -25.1% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -1.41 |
| Piotroski F-Score | 2 |